Serial changes of international prostate symptom score following I-125 prostate brachytherapy

Toshio Ohashi, Atsunori Yorozu, Kazuhito Toya, Shiro Saito, Tetsuo Momma

研究成果: Article

20 引用 (Scopus)

抄録

Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

元の言語English
ページ(範囲)320-325
ページ数6
ジャーナルInternational Journal of Clinical Oncology
11
発行部数4
DOI
出版物ステータスPublished - 2006 8
外部発表Yes

Fingerprint

Brachytherapy
Prostate
Group Psychotherapy
Iodine
Prostatic Neoplasms
Radiotherapy
Therapeutics
Multivariate Analysis

ASJC Scopus subject areas

  • Oncology

これを引用

Serial changes of international prostate symptom score following I-125 prostate brachytherapy. / Ohashi, Toshio; Yorozu, Atsunori; Toya, Kazuhito; Saito, Shiro; Momma, Tetsuo.

:: International Journal of Clinical Oncology, 巻 11, 番号 4, 08.2006, p. 320-325.

研究成果: Article

Ohashi, Toshio ; Yorozu, Atsunori ; Toya, Kazuhito ; Saito, Shiro ; Momma, Tetsuo. / Serial changes of international prostate symptom score following I-125 prostate brachytherapy. :: International Journal of Clinical Oncology. 2006 ; 巻 11, 番号 4. pp. 320-325.
@article{df226f7b7d2e483c96485985adb48194,
title = "Serial changes of international prostate symptom score following I-125 prostate brachytherapy",
abstract = "Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8{\%}) and it returned to within 3 points of the baseline in 64 (62.1{\%}) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.",
keywords = "Brachytherapy, Iodine-125, IPSS, Prostate cancer, Urinary morbidity",
author = "Toshio Ohashi and Atsunori Yorozu and Kazuhito Toya and Shiro Saito and Tetsuo Momma",
year = "2006",
month = "8",
doi = "10.1007/s10147-006-0584-3",
language = "English",
volume = "11",
pages = "320--325",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Serial changes of international prostate symptom score following I-125 prostate brachytherapy

AU - Ohashi, Toshio

AU - Yorozu, Atsunori

AU - Toya, Kazuhito

AU - Saito, Shiro

AU - Momma, Tetsuo

PY - 2006/8

Y1 - 2006/8

N2 - Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

AB - Background. This study was conducted to assess serial changes in the International Prostate Symptom Score (IPSS) within the first 12 months after iodine-125 (I-125) prostate brachytherapy. Methods. Between September 2003 and June 2004, a group of 103 patients with localized prostate cancer was treated with I-125 prostate brachytherapy, either alone (monotherapy; 60 patients) or in combination with external-beam radiotherapy (combined therapy; 43 patients). The IPSS was obtained at preimplant, and at 1, 6, and 12 months after treatment. The minimum IPSS follow-up for this study was 12 months. Dosimetry was based on computed tomography (CT) scan 1 month postimplant. Clinical, treatment-related, and dosimetric factors were assessed for correlations with the maximum IPSS increase (the peak IPSS minus the preimplant IPSS). Results. The median preimplant IPSS was 7.0, with a median peak of 16 at 1 month. The IPSS returned to baseline in 42 patients (40.8%) and it returned to within 3 points of the baseline in 64 (62.1%) at 1-year follow-up. On univariate and multivariate analyses, the maximum IPSS increase was best predicted by lower preimplant IPSS, in both the monotherapy and combined therapy groups. Conclusion. In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 12 months.

KW - Brachytherapy

KW - Iodine-125

KW - IPSS

KW - Prostate cancer

KW - Urinary morbidity

UR - http://www.scopus.com/inward/record.url?scp=33748094619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748094619&partnerID=8YFLogxK

U2 - 10.1007/s10147-006-0584-3

DO - 10.1007/s10147-006-0584-3

M3 - Article

C2 - 16937307

AN - SCOPUS:33748094619

VL - 11

SP - 320

EP - 325

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -